Carbohydrate antigens as targets for antitumor immunotherapy;Immunothérapie anti-tumorale ciblée sur des antigènes osidiques

Revue Francophone des Laboratoires

Volumn 2006, Issue 381, 2006, Pages 39-46

  Bay, Sylvie ^a   Freire, Teresa ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antig ne associ aux tumeurs; cancer; carbohydrate; immunoth rapie; immunotherapy; oside; Tumor associated antigen; vaccin; vaccine

Indexed keywords

EID: 33748772556     PISSN: 1773035X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-035X(06)80150-4     Document Type: Article

References (47)

1. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
2. Antoine T., Heyraud A., Bosso C., and Samain E. Highly efficient biosynthesis of the oligosaccharide moiety of the GD3 ganglioside by using metabolically engineered Escherichia coli, Angew. Chem. Int. Ed. Engl. 44 (2005) 1350-1352
3. Antoine T., Priem B., Heyraud A., Greffe L., Gilbert M., Wakarchuk W.W., Lam J.S., and Samain E. Largescale in vivo synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered Escherichia coli. Chembiochem. 4 (2003) 406-412
4. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nature Rev. Immunol. 5 (2005) 296-306
5. Bay J.O., Penault-Llorca F., Ravaud A., Chevreau C., Negrier S., and Escudier B. New entities in pathological classification and new therapeutic options in renal cell carcinoma. Bull. Cancer 93 (2006) 91-100
6. Bay S., Lo-Man R., Osinaga E., Nakada H., Leclerc C., and Cantacuzène D. Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen: a possible approach to a synthetic carbohydrate vaccine. J. Peptide Res. 49 (1997) 620-625
7. Belardelli F., Ferrantini M., Parmiani G., Schlom J., and Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?. Cancer Res. 64 (2004) 6827-6830
8. Bitton R.J. Cancer vaccines: a critical review on clinical impact. Curr. Opin. Mol. Ther. 6 (2004) 17-26
9. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
10. Borman S. Carbohydrate vaccines. Chem. Eng. News 82 (2004) 31-35
11. Brocke C., and Kunz H. Synthesis of tumor associated glycopeptide antigens. Bioorg. Med. Chem. 10 (2002) 3085-3112
12. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1473 (1999) 67-95
13. Chapman P.B., Morrisey D., Panageas K.SS., Williams L., Lewis J.J., Israel R.J., Hamilton W.B., and Livingston P.O. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin. Cancer Res. 6 (2000) 4658-4662
14. Danishefsky S.J. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines, Angew. Chem. Int. Ed. 39 (2000) 836-863
15. Dube D.H., and Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4 (2005) 477-488
16. Durrant L.G., and Spendlove I. Cancer vaccines entering phase III clinical trials. Expert Opin. Emerg. Drugs 8 (2003) 489-500
17. Dziadek S., Hobel A., Schmitt E., and Kunz H. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-Cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. 44 (2005) 7630-7635
18. Endo T., Koizumi S., Tabata K., Kakita S., and Ozaki A. Large-scale production of the carbohydrate portion of the sialyl-Tn epitope, alpha-Neup5Ac-(2->6). D-GalpNAc, through bacterial coupling. Carbohydr. Res. 330 (2001) 439-443
19. Finn O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3 (2003) 630-641
20. Fuster M.M., and Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5 (2005) 526-542
21. Grigalevicius S., Chierici S., Renaudet O., LoMan R., Derlaud E., Leclerc C., and Dumy P. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjugate Chem 16 (2005) 1149-1159
22. Grogan M.J., Pratt M.R., Marcaurelle L.A., and Bertozzi C.R. Homogeneous glycopeptides and glycoproteins for biological investigation. Annu. Rev. Biochem. 71 (2002) 593-634
23. Kagan E., Ragupathi G., Yi S.S., Reis C.A., Gildersleeve J., Kahne D., Clausen H., Danishefsky S.J., and Livingston P.O. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer lmmunol. Immunother. 54 (2005) 424-430
24. Keding S.J., and Danishefsky S.J. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl. Acad. Sci. USA 101 (2004) 11937-11942
25. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Emstoff M.S., and Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19 (2001) 2370-2380
26. Knutson K.L. Cancer vaccines: the next generation. Drug Discov. Today Therap. Strat. 2 (2005) 323-330
27. Kudryashov V., Glunz P.W., Williams L.J., Hintermann S., Danishefsky S.J., and Lloyd K.O. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering carrier structure, and adjuvant all influence antibody responses to Lewis (Y) conjugates in mice. Proc. Natl. Acad. Sci. USA 98 (2001) 3264-3269 6
28. Lo-Man R., Vichier-Guerre S., Dériaud E., Bay S., Cantacuzene D., and Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide (MAG) displaying a tri-Tn glycotope. J Immunol. 166 (2001) 2849-2854
29. Lo-Man R., Vichier-Guerre S., Perraut R., Deriaud E., Huteau V., BenMohamed L., Diop O.M., Livingston P.O., Bay S., and Leclerc C. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64 (2004) 4987-4994
30. Love K.R., and Seeberger P.H. Automated solidphase synthesis of protected tumor-associated antigen and blood group determinant oligosaccharides. Angew. Chem. Int. Ed. 43 (2004) 602-605
31. Pijpers F., Faint R., and Saini N. Therapeutic cancer vaccines. Nat. Rev. Drug. Dscov. 4 (2005) 623-624
32. Plante O.J., Palmacci E.R., and Seeberger P.H. Automated solid-phase synthesis of oligosaccharides. Science 291 (2001) 1523-1527
33. Ragupathi G., Cappello S., Yi S.S., Canter D., Spassova M., Bommann W.G., Danishefsky S.J., and Livingston P.O. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20 (2002) 1030-1038
34. Ragupathi G., Coltart D.M., Williams L.J., Koide F., Kagan E., Allen J., Harris C., Glunz P.W., Livingston P.O., and Danishefsky S.J. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl. Acad. Sci. USA 99 (2002) 13699-13704
35. Ragupathi G., and Livingston P. The case for polyvalent cancer vaccines that induce antibodies. Expert Rev. Vaccines 1 (2002) 193-206
36. Raman R., Raguram S., Venkataraman G., Paulson J.C., and Sasisekharan R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat. Methods 2 (2005) 817-824
37. Roy R. New trends in carbohydrate-based vaccines. Drug Discov. Today 1 (2004) 327-336
38. Slingluff C.L., and Speiser D.E. Progress and controversies in developing cancer vaccines. J. Transl. Med. 3 (2005) 18
39. Slovin S.F., Keding S.J., and Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell. Biol. 83 (2005) 418-428
40. Slovin S.F., Ragupathi G., Femandez C., Jefferson M.P., Diani M., Wilton A.S., Powell S., Spassova M., Reis C., Clausen H., Danishefsky S., Livingston P., and Scher H.I. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine 23 (2005) 3114-3122
41. Slovin S.F., Ragupathi G., Musselli C., Olkiewicz K., Verbal D., Kuduk S.D., Schwarz J.B., Sames D., Danishefaky S., Livingsten P.O., and Scher H.J. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21 (2003) 4292-4298
42. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., Schwientek T., Graham R., Taylor-Papadimitriou J., Hollingsworth M.A., Burchell J., and Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16 (2006) 96-107
43. Toyokuni T., Hakomori S., and Singhal A.K. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg. Med. Chem. 16 (2006) 96-107
44. Toyokuni T., Hakomori S., and Singhal A.K. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorg. Med. Chem. 2 (1994) 1119-1132
45. Witte K., Sears P., Martin R., and Wong C.H. Enzymatic glycoprotein synthesis: preparation of ribonuclease glycoforms via enzymatic glycopeptide condensation and glycosylation. J. Am. Chem. Soc. 119 (1997) 2114-2118
46. Wong C.H. Protein glycosylation: new challenges and opportunities. J. Org. Chem. 70 (2005) 4219-4225
47. Zhang Z.Y., Ollmann I.R., Ye X.S., Wischnat R., Baasov T., and Wong C.H. Programmable one-pot oligosaccharide synthesis. J. Am. Chem. Soc. 121 (1999) 734-753